The AKT (murine thymoma viral (v-akt) oncogene homologue), also termed protein kinase B (PKB) or RAC protein kinase, is a serine and threonine protein kinase homologous to protein kinases A and C [1] [2] .
IRS1 and IRS2, have shown that insulin-signalling pathways are important for beta cell growth and function [3, 4] . The AKT has been shown to be an important downstream target of the insulin-signalling pathway. More recently, pancreatic islet beta cell-specific AKT1 transgenic mice were observed to have a much higher beta cell mass and insulin content, suggesting that AKT1 could be a key regulator in normal beta cell growth [5] . Our reverse transcriptase (RT)-PCR analysis of insulinoma cell (MIN6) mRNA showed that AKT1 was the predominant isoform in this beta cell line (H. Inoue, unpublished observation).
In view of the fact that genetic defects in the AKT1 gene could be associated with either impaired insulin action, beta cell growth or both, we considered whether this gene could predispose to Type II (noninsulin-dependent) diabetes. A previous study has examined genetic variants in AKT1 in 70 Danish Caucasian patients with Type II diabetes [6] . Because the genomic structure of AKT1 was not known, the investigators carried out RT-PCR of AKT1 mRNA isolated from skeletal muscle biopsies. The resulting products were analysed by single strand conformational polymorphism and heteroduplex analysis revealing a single variant (Tyr  tac 417Tyr tat ) with allelic frequency of 2 %. In this study, we isolated the human AKT1 gene from large insert bacterial clones of human genomic DNA, characterized its structure, and tried to identify potential mutations in the gene in patients with Type II diabetes. Altogether 13 intragenic single nucleotide polymorphisms (SNPs) were identified and the allelic frequencies of 6 SNPs belonging to Ashkenazi Jewish patients with Type II diabetes and control subjects were compared.
Subjects and methods
General molecular biological procedures. Standard molecular biology techniques were used [7] . Taq-Gold DNA polymerase was purchased from Perkin-Elmer/Cetus (Foster City, Calif., USA), and PCR amplification was done according to the supplier's protocols. Restriction enzymes and other modification enzymes were purchased from NEB (Beverly, Mass., USA) and Promega (Madison, Wis., USA). Oligonucleotides were synthesized in the Protein Chemistry Laboratory, Washington University School of Medicine. DNASTAR software (Madison, Wis., USA) was used for analysis of DNA sequences.
Subjects and genomic DNA. All subjects were participants in a genome scan of Type II diabetes in Ashkenazi Jews as described previously [8] . The study was approved by the institutional review board of Washington University School of Medicine. Type II diabetes was defined according to the 1980±1985 WHO criteria. Genomic DNA was extracted from whole blood using the Puregene Genomic DNA extraction kit (Gentra System, Minneapolis, Minn., USA). For the SNP screening by denaturing high-performance liquid chromatography (DHPLC), 30 unrelated probands who had the highest evidence of linkage to chromosome 14 q based on the identity-by-descent (IBD) probability of 5 markers between D14S606 and D14S267 were selected from a large set of affected sib pairs [8] . An association study using individual SNPs was carried out by comparing allelic and genotypic frequencies in Type II diabetes patients (n = 69) and control subjects (n = 65). The average fasting plasma glucose concentrations and HbA 1 c of diabetic patients were 178.5 7.8 mg/dl and HbA 1 c 9.0 0.2 %, respectively. Mean BMI of Type II diabetic patients was higher than that of control subjects (29.3 0.7 vs. 25.5 0.4 kg/m 2 , mean -SEM, p < 0.001). The ages of the two groups differ (p < 0.001) because patients (55.0 1.2 years) were initially recruited only if Type II diabetes was present in at least one family member who was under 55 years of age, and control subjects were selected for normal glucose tolerance by 75 g OGTT in an older population (75.4 1.1 years) [8] .
Isolation of human genomic clones and DNA sequencing. To isolate human AKT1 genomic clones, PCR primers were selected from the published sequence of the human AKT1 cDNA (GenBank Accession NM_005 163). One set of primers was chosen from the 3'-untranslated region of this cDNA sequence, AKT1F1: 5'-CACCAGATGCAACCTCACTA-3', AKT1R1: 5'-TAAACCTTGCTCCTCTGTCC-3' (185 bp, primer annealing sites at nt. positions 2076±2095 and 2241±2260, respectively). Another set was chosen from the 5'-end of the cDNA sequence, AKT1F2: 5'-GCCTGGGTC-AAAGAAGTCAA-3', AKT1R2: 5'-TAGCCACGTCGCTC-ATGGTG-3' (approximately 600 bp, primer annealing sites at nt. positions 58±77 and 195±214, respectively). The AKT1F1 and AKT1R1 were used for radiation hybrid mapping using the GeneBridge 4 panel (Research Genetics, Huntsville, Ala., USA). The human genomic BAC library (CITB Human BAC Library, Research Genetics) and P1 library (HDK) were screened by PCR, using primers AKT1F1/AKT1R1 and AKT1F2/AKT1R2, respectively [9] . To obtain structural information and intronic sequences of the AKT1 gene, the BAC and P1 DNA clones were purified and sequenced with an ABI Automated Sequencer Model 377 using the ABI Prism BigDye Terminator Cycle Sequencing kit (PE Applied Biosystems, Foster City, Calif., USA). By comparing the sequences obtained and the reported cDNA sequence, intron-exon boundaries were determined and the BAC/P1 sequencing was continued until the entire coding sequence and exon-intron boundaries were obtained.
SNP identification and genotyping. For SNP screening, heteroduplexes of PCR products from each patient with those from a control homozygous individual (wild-type DNA) were analysed by the DHPLC using a Transgenomic WAVE HPLC (Transgenomic, Omaha, Neb., USA) and DNASep column (Transgenomic) following the manufacturer's instructions. DNA fragments with aberrant elution profiles were re-amplified and sequenced directly. For genotyping individual SNPs, PCR products were digested with restriction enzymes shown in Table 1 and analysed by agarose-gel electrophoresis.
Statistical analysis. Differences between groups in allelic and genotypic frequencies were assessed by Fisher's exact test and chi-square tests, with Yates' correction as needed (InStat, GraphPad Software, San Diego, Calif., USA). Linkage disequilibrium (allelic associations) between pairs of SNPs was assessed by the ASSOCIATE program (http://linkage.rockefeller.edu/ott/linkutil.htm). A p value of less than 0.05 was considered statistically significant.
Results
Isolation and characterization of the human AKT1 gene. The BAC clone (CITB150E7) did not contain the 5'-end of the AKT1 gene. The P1 (HDK45E6) clone did not contain the 3'-end. These clones overlapped with each other and covered the entire coding region of the AKT1 gene. The human AKT1 gene was estimated to be at least 24.6 kb in length and to be composed of 14 exons, with the first ATG and open reading frame observed in exon 2 (GenBank Accession numbers AF283818-AF283 830). All exon/intron junctions of AKT1 contain consensus donor/splice junctions. A sequence comparison of our genomic, reference cDNA and the EST sequences showed an exact sequence match up to 492 bp of 5'-untranslated sequence of the AKT1 gene but we did not map precise transcription initiation site(s). Thus, the possibility of an additional exon(s) encoding an additional 5'-untranslated region cannot be fully excluded.
The human AKT1 gene was previously mapped to chromosome 14 q in a human-rodent somatic hybrid panel and to 14q32.32 by in situ hybridization (UniGene # Hs.71 816). Two-point RHMAP analysis of our RH results at the Sanger RH Mapping Server (http://www.sanger.ac.uk/Software/RHserver/) indicated that the gene was linked to a polymorphic marker (D14S272), with a lod score of 12.651. The D14S272 has been previously mapped at 124.2 cM on chromosome 14 (1996 Genethon map), and at 14q32.1±14q32.3 by Chr 14 Cytogenetic Map (HUGO Chromosome Committee 14). Further, the multipoint RHMAPPER option placed the gene within RH framework interval no. 37 on the 1998 Gene Map (http:www.ncbi.nlm.nih.gov/genemap98/), the most telomeric region on chromosome 14 between D14S272 (275.98 cR) -qTEL (290.71 cR).
SNP identification. All 14 exons with flanking intronexon junctions of the AKT1 gene were examined. Altogether 13 putative intragenic SNPs were detected.
Of these, 1 encoded a silent codon change in exon 9 (SNP9; Glu gaa 242Glu gag ) and 11 were intronic variants that did not seem to have any functional consequences, as they did not affect splice junctions. The remaining SNP (SNP1; c.-350 G®T) was located at the very 5'-end of the gene. Using the dbEST database, we found two EST sequences (GenBank Accession H41 956 and AI597 912) that matched this 5'-variant. Thus we concluded that SNP1 is located in the 5'-untranslated region of exon 1. Of note , the single AKT1 SNP previously reported in 2 % of Danish Caucasian patients with Type II diabetes (Tyr tac 417-Tyr tat ) was not found in our population [6] . In this study, we did not look for the promoter and other regulatory sequence(s) for polymorphisms for the reasons mentioned above.
Altogether nine of these variants either created or abolished restriction endonuclease sites in genomic DNA. The frequencies of these variants were subsequently determined in at least 24 control subjects by PCR-RFLP analysis (Table 1) . Based on the results of these frequencies and locations within the gene, six SNPs (SNP1, 4, 5, 9, 12 and 13) were used for subsequent analysis. 
Discussion
Linkage disequilibrium (LD) and association studies.
The allelic and the genotypic frequencies of the six SNPs were the same for patients with Type II diabetes and control subjects.
To obtain an idea of the physical distances over which LD could be expected to be found at the AKT1 locus in the Ashkenazi Jewish population, the extent of LD between pairs of SNPs (SNP1, 4, 5 and 9) was determined. Statistically significant LD was observed in both groups for pairs of closely spaced SNPs ( < 14 kb). Of note, SNP1 in the 5'-end of the gene was randomly associated with other SNPs only slightly more than 17 kb away in the 3'-end (SNP1-SNP5, SNP1-SNP9), reinforcing previous concern that genome scans with SNP associations could require markers spaced at less than 3 kb intervals [10] .
In summary, we conclude that the AKT1 gene probably does not contribute to susceptibility to Type II diabetes in the Ashkenazi Jewish population. A better understanding of the genomic structure and the detection of informative intragenic SNPs, could, however, throw light on any role this gene might have in the pathogenesis of diabetes in other racial groups or in other diseases. 
